Rossari Biotech (ROSSARI) Q4 25/26 earnings summary

Executive summary

• Achieved highest-ever quarterly and annual revenue and EBITDA in Q4 and FY26, with all core segments delivering double-digit growth year-over-year, supported by a diversified portfolio and international expansion.

• Resilience shown despite raw material volatility and geopolitical disruptions, with healthy growth in all key segments.

• Strategic focus on R&D, innovation, and capacity expansion, including new R&D facility in Navi Mumbai and increased ethoxylation capacity.

• Audited standalone and consolidated financial results for FY 2025-26 approved, with an unmodified audit opinion.

• Ongoing cost optimization and portfolio rationalization, especially in underperforming institutional and B2C businesses.

Financial highlights

• Q4 FY26 revenue: ₹684.9 cr (up 18.2% YoY); EBITDA: ₹77.3 cr (up 11.2% YoY); PAT: ₹46.0 cr (up 33.7% YoY).

• FY26 consolidated revenue: ₹2,396.4 cr (up 15.2% YoY); EBITDA: ₹286.0 cr (up 88% YoY); PAT: ₹149.2 cr (up 9.4% YoY); EBITDA margin: 11.9%.

• Gross margins impacted by sales mix and raw material price increases, some passed on to customers.

• Excluding institutional and B2C, core B2B operations delivered 14% EBITDA margin.

• Gain of ₹19 cr (₹192.67 million) from sale of office space as part of non-core asset liquidation.

Outlook and guidance

• FY27 growth expected to match or exceed FY26, contingent on global conditions; new capacities and EO supply to support growth.

• EBITDA margins guided at 12%-13% for FY27, with improvement expected from entry into higher-margin segments like pharma.

• Focus on disciplined execution, capacity utilization, and margin enhancement through product mix and cost control.

• Capacity expansion project to be executed in phases over two years, reflecting evolving business needs.

• Targeting minimum 15% revenue growth, with drivers including pharma, agro, oil & gas, and international expansion.